Idenix restructures, cuts workforce

Idenix Pharmaceuticals is shifting its R&D operations away from its hepatitis B treatment Tyzeka to focus on the development of hepatitis C virus and HIV programs. Idenix has amended its agreement with Novartis so that Novartis will take over all activities related to Tyzeka. Idenix is also reducing its workforce by approximately 100 positions, the majority of which support the development and commercialization of Tyzeka, saving the company as much as $45 million.

"We have taken the steps necessary to streamline our organization and significantly reduce our expenses, while continuing to maintain the strength of our balance sheet," said Ronald Renaud, Jr., chief financial officer of Idenix. "We believe that we are now well-positioned to fund the advancement of our HIV and HCV discovery and development programs through 2009."

- see this release for more

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.